Despite falling short of analyst expectations, Tyra Biosciences is taking its cancer drug to registrational development for ...

Prostate cancer is the second most common form of cancer among men globally. Yet, we still know relatively little about why ...

The Iowa Board of Regents approved requests for the creation of the Institute of Cancer Drug Discovery and Development, or ...

The order of cancer-driving mutations—genetic changes—plays an important role in whether tumors in the intestine can develop, new research reveals. These are the findings published on 3 December in ...

Cancer is one of the most widely discussed health conditions in the world. It is not a single disease but a broad group of diseases ...

Enhancing Readability of Lay Abstracts and Summaries for Urologic Oncology Literature Using Generative Artificial Intelligence: BRIDGE-AI 6 Randomized Controlled Trial We trained and tested ML systems ...

Short-Term Surgical Mission in Sub-Saharan Country, Experience of a Breast-Dedicated Team: Reviewing the Past and Stepping Toward the Last Mission Rapidly expanding systemic treatment options, ...

Dec 16 (Reuters) - Merck (MRK.N), opens new tab said on Monday it has discontinued the development of two experimental cancer drugs after their failure in several trials. The pharmaceutical giant's ...